Clinical trials: Schizophrenia
Schizophrenia
Program for the Introduction Into Clinical Practice of the Principles of Personalized and Preventive Medicine Based on the Isolation of Gene Polymorphism in Schizophrenia in People of the Kazakh Ethnic Group
This is a GWAS study that aims to identify possible candidate genes associate to schizophrenia by exploring single nucleotide polymorphism (SNP) in a group of schizophrenia, in the Kazakh population.
- Trial name
- NCT05090644
- Testing
- DNA analysis
- Where
- Kazakhstan
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Asfendiyarov Kazakh National Medical University
Treatment-refractory Schizophrenia
Electroconvulsive Therapy for Treatment Refractory Schizophrenia - A Randomized, Double-blinded, Sham-controlled Study
The purpose of the study is to determine whether addition of electroconvulsive therapy to antipsychotic treatment improves the mental health of patients with treatment-resistant schizophrenia.
- Trial name
- NCT01948999
- Testing
- ECT, Anesthesia
- Volunteers
- 3 people
- Sponsor
- University of Aarhus
Schizophrenia and Disorders With Psychotic Features
One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome
The purpose of this study is to explore the impact of ziprasidone on the distribution of metabolic syndrome risk factors in a population of patients presenting with glucose intolerance, dyslipidemia and/or elevated waist…
- Trial name
- NCT00748566
- Testing
- Ziprasidone HCL (oral)
- Where
- 32 sites in Canada
- Volunteers
- 172 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Schizoaffective Disorder
Adapted Cognitive/Affective Remediation for Cannabis Misuse in Schizophrenia
This study will integrate and adapt a cognitive remediation (Cognitive Enhancement Therapy [CET]) and an affect regulation (Personal Therapy [PT]) intervention for 50 individuals with schizophrenia that misuse cannabis.
- Trial name
- NCT01292577
- Testing
- CET/PT, Treatment as Usual
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Pittsburgh
Substance Use Disorders, Depression
A Novel Person-Centered Treatment Component for Substance Use Treatment
A person-centered substance use treatment component, the Natural Recovery Program, was developed in a residential substance use treatment setting.
- Conditions
- Substance Use Disorders, Depression, Bipolar Disorder, Psychosis
- Trial name
- NCT02005367
- Testing
- Natural Recovery-Horticulture, Natural Recovery-Art/Music
- Where
- United States
- Volunteers
- 643 people
- Sponsor
- Hampton VA Medical Center
Hyperprolactinemia, Weight Gain
Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia
This is a prospective, open-label study to evaluate the efficacy and safety in reducing antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole.
- Conditions
- Hyperprolactinemia, Weight Gain, Dyslipidemia
- Trial name
- NCT00541554
- Testing
- Abilify (aripiprazole)
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Schizophrenia
Sex Differences in NMDA-enhancing Treatment of Schizophrenia
Schizophrenia differs between sexes in clinical symptoms and functional outcome. Negative symptoms are the core pathology of this disease. NMDA receptor (NMDAR) dysfunction is a key factor in negative symptoms.
- Trial name
- NCT07122895
- Testing
- NMDAE
- Where
- Taiwan
- Volunteers
- 90 people
- Sponsor
- China Medical University Hospital
Schizophrenia, Cognition
Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic
This is a study of the effects of tDCS on smoking, craving for cigarettes, cognition, and psychiatric symptoms in schizophrenic patients who are current smokers or have a history of regular cigarette smoking.
- Conditions
- Schizophrenia, Cognition, Cigarette Smoking
- Trial name
- TDCSSCHIZ (NCT02128919)
- Testing
- tDCS
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Nathan Kline Institute for Psychiatric Research
Schizophrenia, Schizoaffective Disorder
Effect of Single Dose Intranasal Insulin On Cognitive Function
The purpose of the study is to find out how a small dose of insulin might affect memory, the ability to concentrate, and improve your daily functioning in patients with schizophrenia and schizoaffective disorders.
- Trial name
- NCT00646581
- Testing
- Insulin (Humulin)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Metabolic Evaluation, Cardiac Complications
Metabolic and Clinical Effect of Alpha-lipoic Acid Administration in Schizophrenic Subjects
The therapeutic use of ALA in schizophrenia has recently been investigated in human populations. A case series explored the effiacy of ALA as a novel agent to treat antipsychotic-induced obesity, at a dose of 1200 mg/d (range…
- Trial name
- NCT06787781
- Testing
- Alpha Lipoic Acid
- Where
- Italy
- Volunteers
- 15 people
- Sponsor
- University of Messina
Schizophrenia
The Treatment Efficacy of Combination Atypical Antipsychotics With Sertraline in Patients With Schizophrenia
A randomized, double-blind trial of the treatment effect of dose-low antipsychotics combined with low-dose sertraline in 1640 schizophrenia patients
- Trial name
- NCT04076371
- Testing
- olanzapine-sertraline combination, only olanzapine, risperidone-sertraline combination
- Volunteers
- 1,640 people
- Sponsor
- Beijing HuiLongGuan Hospital
Bipolar Disorder, Schizoaffective Disorder
Comparison of Combination Olanzapine+Lithium or Chlorpromazine+Lithium in Treatment of First Manic Episode With Psychotic Features
Aim: In a population of first episode manic patients with psychotic features, we want to compare the side effect profile, the degree of adherence and the subjective well being, as well as the efficacy of two treatments: The…
- Trial name
- NCT00202293
- Testing
- Olanzapine, Lithium, Chlorpromazine
- Where
- Australia
- Volunteers
- 83 people
- Sponsor
- Melbourne Health
Schizophrenia
PREvent First Episode Relapse (PREFER)
Many patients who have recently received a diagnosis of schizophrenia (e.g., "first-episode schizophrenia") respond very well to their antipsychotic medication when they are acutely ill.
- Trial name
- NCT00220714
- Testing
- atypical antipsychotics:oral vs. long-acting route, Family Psychoeducation
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- State University of New York - Downstate Medical Center
Schizophrenia; Psychosis
The IM-ZBULLE Study : " Z-track " and " Airlock " Techniques During Intramuscular Injection of Haloperidol Decanoate
Intramuscular injection (IMI) is the process of administering a drug treatment into muscle tissue. The transmission of skills in this care practice is essentially based on the experience of peers.
- Trial name
- IM-ZBULLE (NCT05995457)
- Testing
- Intramuscular injection of Haloperidol decanoate using the "Z-track" and "Airlock" techniques, Intramuscular injection of Haloperidol decanoate using standard techniques
- Where
- France
- Volunteers
- 84 people
- Sponsor
- Centre Hospitalier St Anne
Schizophrenia
Switching to Iloperidone From Other Antipsychotics in Schizophrenia
Evaluate the clinical outcome of two switching strategies to iloperidone treatment in adult subjects with schizophrenia who require a change in their current antipsychotic treatment of risperidone, olanzapine, or aripiprazole due…
- Trial name
- i-FANS (NCT01207414)
- Testing
- iloperidone
- Where
- 59 sites in United States
- Volunteers
- 501 people
- Sponsor
- Novartis
Schizophrenia, Schizoaffective
The Consta Club: A Demonstration Project for Setting up a Consta Club in a Community Mental Health Center
This study will establish a bi-weekly Consta Club. Participants will begin taking Risperdal Consta after being recommended by their treating physician.
- Trial name
- NCT00845572
- Testing
- Consta Club
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Schizophrenia, Bipolar Disorder
Impact of Cognitive & Metacognitive Performance on Knowledge Learning When Conducting Therapeutic Education Programs
People with schizophrenia and bipolar disorder display alterations in cognition and metacognition. These alterations may have an impact on learning during therapeutic education programs.
- Trial name
- MetaCOGNITION (NCT04590300)
- Testing
- QUESTIONNAIRES
- Where
- France
- Volunteers
- 108 people
- Sponsor
- Centre Hospitalier Charles Perrens, Bordeaux
Major Depressive Disorder
An International Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression
Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress…
- Trial name
- NCT00146523
- Testing
- Mifepristone
- Where
- 19 sites in Bulgaria, Croatia and 2 more
- Volunteers
- 247 people
- Sponsor
- Corcept Therapeutics
Psychotic Disorder
The Effect of D-serine as add-on Therapy in Recent-onset Psychosis
In psychotic disorders, negative symptoms and cognitive impairment are difficult to treat with antipsychotics, which are mostly effective for positive symptoms.
- Trial name
- DROP (NCT04140773)
- Testing
- D-serine
- Where
- Switzerland
- Volunteers
- 3 people
- Sponsor
- Dragos Inta
Psychotic Disorders
Hormonal and Inflammatory Biomarkers and Response to Cognitive Remediation in Recent-onset Psychosis
This study aims to explore whether hormones or inflammatory markers are associated with cognitive changes following cognitive remediation therapy (CRT) in people with a recent-onset psychotic disorder.
- Trial name
- NCT04418570
- Testing
- cognitive remediation, attendance to an Early Intervention Service for Psychosis
- Volunteers
- 28 people
- Sponsor
- Corporacion Parc Tauli